Trial · NCT07906717
A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
NCT07906717, Phase 3, Recruiting, Janssen Research & Development, LLC
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer. Trials, record NCT07906717. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07906717
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study of JNJ-101556143 With Best Supportive Care in Participants With Metastatic Prostate Cancer
- NCT number
- NCT07906717
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 400 participants, estimated
- Lead sponsor
- Janssen Research & Development, LLC
- Conditions
- Prostatic Neoplasms
- Interventions
- JNJ-101556143, Placebo, Best Supportive Care
- First posted
- 2026-10-30
- Last updated
- 2026-11-03
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Overall Survival (OS) | Up to 21 months | OS is defined as the time from randomization to date of death from any cause. |
| Secondary | Radiographic Progression-Free Survival (rPFS) | Up to 21 months | rPFS is defined as the time from the date of randomization until the date of radiographic disease progression or death, whichever comes first as per response evaluation criteria in solid tumors version 1.1 (RECIST v1.1) and Prostate Cancer Working Group 4 (PCWG4) criteria. |
| Secondary | Progression-Free Survival (PFS) | Up to 21 months | PFS is defined as the time from randomization until disease progression or death, whichever occurs first. |
| Secondary | Time to Symptomatic Progression (TSP) | Up to 21 months | TSP is defined as the time from the date of randomization to the date of the first occurrence of any of the following: The use of external beam radiation for palliative treatment; need for tumor-related orthopedic surgical intervention; other cancer-related procedures; cancer-related morbid events and initiation of a new systemic anticancer therapy because of cancer symptoms. |
| Secondary | Time to Skeletal-Related Events (TSRE) | Up to 21 months | TSRE is defined as the time from the date of randomization to the date of the first occurrence of any of the following (whichever occurs first): * The use of external beam radiation therapy to relieve skeletal symptoms. * The need for tumor-related orthopedic surgical intervention. * The occurrence of new bone fractures (cancer-related; vertebral or non-vertebral). * The occurrence of tumor-related spinal cord compression. |
| Secondary | Time to Pain Progression (TTPP) | Up to 21 months | TTPP is defined as the time from the date of randomization to first observation of pain progression. Pain progression is defined as an increase of \>=2 points from baseline in the BPI-SF worst pain intensity (item 3) observed at 2 consecutive evaluations \>=3 weeks apart with no decrease in analgesic dose. |
| Secondary | Number of Participants with Treatment-Emergent Adverse Event (TEAE) by Severity | Up to 21 months | An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Severity will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE). Severity scale defined as Grade 1= Mild, Grade 2= Moderate, Grade 3= Severe, Grade 4= Life-threatening and Grade 5= Death related to adverse event. |
| Secondary | Number of Participants with Abnormalities in Clinical Laboratory Tests | Up to 21 months | Participants with abnormalities in clinical laboratory tests will be reported. |
| Secondary | Plasma Concentration of JNJ-101556143 | Pre-dose for Cycles 1 to 4; 2 to 3 hours and 4 to 8 hours Post-dose from Cycles 1 to 2 (each cycle duration is 28 days) | Plasma samples will be analyzed to determine concentrations of JNJ-101556143 using a validated LC-MS/MS method. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07906717
GET https://conductscience.org/api/trials/v1/NCT07906717/registered